Scott Kober

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The cost of biologic therapies adds urgency to the need to develop realistic compliance strategies. By engaging and educating both the physician and patient, some MCOs are working hard to address at what has always been a complicated and formidable issue.
Biotech's course through 2005 will hinge on five key variables: Use of electronic medical records to speed data collectionClarifying sources of investment capitalKeeping clinicians currentReshaping benefit designs to cope with new and costly productsAnd, above all, defining and proving the value of biotech products Here's a look at how these issues could(More)